"Your trusted healthcare partner"

During the past decade, Pantai Hospital Kuala Lumpur conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 1 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 1 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Pantai Hospital Kuala Lumpur" #1 sponsor was "Arcus Biosciences, Inc." with 1 trials, followed by "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored, "Incyte Corporation" with 1 trials sponsored, "Janssen Research & Development, LLC" with 1 trials sponsored and "National Cancer Centre, Singapore" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Pantai Hospital Kuala Lumpur" #1 collaborator was "Gilead Sciences" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Singapore General Hospital" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Pantai Hospital Kuala Lumpur" are "Lung Cancer" (4 trials), "Advanced or Metastatic Non-small Cell Lung Cancer" (1 trials), "Non Small Cell Lung Cancer" (1 trials), "Non-Small Cell Lung Cancer" (1 trials) and "Non-small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Pantai Hospital Kuala Lumpur" in a lesser frequency.

Most popular intervention types in "Pantai Hospital Kuala Lumpur" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (2 trials), "Amivantamab Intravenous" (1 trials), "Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)" (1 trials), "Carboplatin" (1 trials) and "Dacomitinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Pantai Hospital Kuala Lumpur" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Pantai Hospital Kuala Lumpur". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Pantai Hospital Kuala Lumpur, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Pantai Hospital Kuala Lumpur, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".